Latest news with #DigitalHealth
Yahoo
7 days ago
- Business
- Yahoo
Alcohol Use Disorder (AUD) Market Trends and Forecasts (2025-2030) by Drug Class, Treatment Type, End User, Distribution Channel, Formulation, Region and Country
Featuring Profiles of Key Players Alkermes, H. Lundbeck, Teva Pharmaceutical Industries, Viatris, Sandoz International and More Dublin, May 29, 2025 (GLOBE NEWSWIRE) -- The "Alcohol Use Disorder Market by Drug Class, Treatment Type, End User, Distribution Channel, Formulation - Global Forecast to 2030" report has been added to Alcohol Use Disorder Market grew from USD 1.28 billion in 2024 to USD 1.37 billion in 2025. It is expected to continue growing at a CAGR of 6.60%, reaching USD 1.88 billion by landscape of AUD treatment is undergoing transformative shifts that redefine conventional paradigms and unlock new avenues for patient engagement. Digital health solutions, exemplified by teletherapeutic platforms and mobile applications, are enhancing adherence and extending the reach of behavioral interventions. Concurrently, regulatory bodies are recalibrating approval pathways to accommodate novel modalities, from sustained-release injectables to adaptive combination therapies. This convergence of technological innovation and regulatory agility accelerates the translation of research breakthroughs into clinical trends further inform strategic pivots, as rising incidence in younger cohorts compels the design of more personalized, stigma-sensitive outreach programs. Pharmaceutical developers are responding by enhancing patient support services and leveraging real-world evidence to optimize dosing regimens. Meanwhile, payers are reassessing reimbursement frameworks to reward value-based outcomes over volume-driven metrics. Collectively, these shifts signal a more integrated, patient-centric future for AUD management, where therapy personalization and outcome measurement coalesce to improve both clinical efficacy and economic the Ramifications of 2025 United States Tariffs on AUD TherapiesThe imposition of United States tariffs in 2025 has reverberated throughout the global supply chain for AUD therapies, prompting a reassessment of sourcing strategies and cost structures. Raw material levies on key active pharmaceutical ingredients have elevated production expenses, particularly for excipients integral to effervescent and sustained-release formulations. Manufacturers reliant on international chemical suppliers have encountered upward price pressure, resulting in margin compression and, in some cases, temporary repricing at the point of mitigate these effects, several drug producers have expedited domestic procurement agreements and invested in localized manufacturing capabilities. While these measures enhance supply chain resilience, they require significant capital outlays and extended lead times. Payers and providers have also felt the ripple effects, with negotiated contract terms evolving to accommodate incremental cost burdens. Amid these market dynamics, strategic collaboration between pharmaceutical companies and contract manufacturers has emerged as a critical lever to safeguard continuity of supply and protect patient access. The collective response underscores the delicate interplay between trade policy and therapeutic availability in the AUD Dynamics Shaping the AUD MarketRegional dynamics exert a powerful influence on the trajectory of AUD treatments. In the Americas, robust healthcare infrastructure and substantial public funding underpin expansive adoption of both pharmacotherapies and integrated behavioral programs. The United States remains the epicenter of innovation, supported by a comprehensive network of academic research centers and a growing emphasis on telemedicine reimbursement. Latin American markets are witnessing gradual uptake, driven by rising incidence rates and policy initiatives aimed at expanding rural healthcare Europe, Middle East and Africa, market maturity varies widely. Western European nations boast well-established reimbursement frameworks and stringent regulatory processes, fostering incremental innovation in drug delivery and patient support models. In contrast, emerging markets in the Middle East and parts of Africa contend with limited infrastructure and variable regulatory oversight, creating both challenges and opportunities for suppliers willing to invest in capacity-building partnerships and localized Asia-Pacific region presents a dual narrative of rapid urbanization and shifting cultural attitudes toward alcohol use. Markets such as China, India and Australia are allocating increased resources toward AUD screening and treatment integration within primary care settings. Government initiatives aimed at destigmatizing behavioral therapy are gaining momentum, while private sector players explore digital therapeutics to overcome geographic barriers. Collectively, these regional insights underscore the necessity of geographically tailored strategies that align with local regulatory environments, payer structures and patient engagement Landscape and Key Industry PlayersThe competitive landscape of AUD therapeutics features established pharmaceuticals alongside emerging biotechnology innovators. Leading companies have fortified their market positions through strategic product life-cycle management, launching reformulated versions and extended-release alternatives to prolong patent exclusivity. Some firms have executed targeted acquisitions to integrate niche behavioral health capabilities or expand geographic reach, while others have forged co-development agreements to share R&D costs and accelerate pipeline entrants are disrupting traditional paradigms by advancing novel delivery systems and repurposing existing compounds for adjunctive use. Several players are exploring advanced drug-device combinations to optimize dosing adherence, while digital health start-ups collaborate with pharmaceutical sponsors on teletherapy platforms that integrate electronic patient-reported outcomes. Formulary negotiations and patient assistance programs have become critical battlegrounds, with manufacturers deploying real-world evidence and health economics data to secure favorable reimbursement this milieu, companies that demonstrate agility in regulatory navigation, supply chain optimization and stakeholder engagement are poised to gain competitive advantage. The continual interplay between legacy portfolio optimization and next-generation product introductions shapes the contours of market leadership and defines the success metrics for future Imperatives for Industry LeadershipIndustry leaders must adopt proactive strategies that anticipate evolving market demands and regulatory shifts. First, deepening investments in digital health integration will bridge gaps between pharmacotherapy and behavioral interventions, enhancing patient retention and improving long-term outcomes. Deploying advanced analytics to personalize treatment pathways can also heighten efficacy and reduce dropout rates. Second, strengthening partnerships with contract manufacturing organizations can mitigate supply chain disruptions triggered by external trade policies, ensuring consistent product availability across diverse forging alliances with payers and provider networks to design value-based reimbursement models will be essential for demonstrating cost-effectiveness and driving formulary placement. Collaborative real-world evidence initiatives can substantiate clinical and economic benefits, paving the way for risk-sharing agreements. Finally, expanding into underserved and emerging markets requires tailored go-to-market approaches that address local infrastructure constraints and cultural attitudes toward behavioral health. By proactively implementing these imperatives, industry stakeholders can navigate uncertainty and secure sustained growth in the accelerating AUD Segmentation & CoverageThis research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations: Drug Class Acamprosate Effervescent Tablet Oral Tablet Disulfiram Oral Tablet Naltrexone Injectable Oral Tablet Treatment Type Behavioral Therapy Cognitive Behavioral Therapy Family Therapy Motivational Enhancement Therapy Combined Therapy CBT With Pharmacotherapy MET With Pharmacotherapy Pharmacotherapy Injectable Drugs Oral Drugs End User Home Healthcare Home Visits Telehealth Hospitals Private Hospitals Public Hospitals Rehabilitation Centers Inpatient Outpatient Specialty Clinics Alcohol Rehabilitation Clinics Psychiatric Clinics Distribution Channel Hospital Pharmacies Private Hospital Pharmacies Public Hospital Pharmacies Online Pharmacies E-Commerce Websites Mobile Apps Retail Pharmacies Chain Pharmacies Independent Pharmacies Specialty Pharmacies AUD Specialty Pharmacies General Specialty Pharmacies Formulation Dispersible Tablet Effervescent Tablet Injectable Intramuscular Intravenous Subcutaneous Oral Tablet Immediate Release Sustained Release This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions: Americas United States California Texas New York Florida Illinois Pennsylvania Ohio Canada Mexico Brazil Argentina Europe, Middle East & Africa United Kingdom Germany France Russia Italy Spain United Arab Emirates Saudi Arabia South Africa Denmark Netherlands Qatar Finland Sweden Nigeria Egypt Turkey Israel Norway Poland Switzerland Asia-Pacific China India Japan Australia South Korea Indonesia Thailand Philippines Malaysia Singapore Vietnam Taiwan This research report categorizes to delves into recent significant developments and analyze trends in each of the following companies: Alkermes plc H. Lundbeck A/S Teva Pharmaceutical Industries Ltd. Viatris Inc. Sandoz International GmbH Dr. Reddy's Laboratories Ltd. Sun Pharmaceutical Industries Ltd. Aurobindo Pharma Ltd. Lupin Limited Cipla Limited Key Attributes Report Attribute Details No. of Pages 192 Forecast Period 2025-2030 Estimated Market Value (USD) in 2025 $1.37 Billion Forecasted Market Value (USD) by 2030 $1.88 Billion Compound Annual Growth Rate 6.6% Regions Covered Global For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Associated Press
28-05-2025
- Business
- Associated Press
Last Call! Global Startups to Get on Board EPIC 2025
Don't Miss Out on the Million-dollar Opportunity at Asia's Most Dynamic Ecosystem HONG KONG SAR - Media OutReach Newswire - 28 May 2025 - The 9th Elevator Pitch International Competition (EPIC 2025), organised by Hong Kong Science and Technology Parks Corporation (HKSTP), has only 3 weeks left for global startups with their anchor in FinTech, and new tech tracks Digital Health and Green Tech, respond to the call to one of Asia's largest innovation arenas. Participants will 60-second pitch their way to business matching and investment opportunities for a lift towards success. Last Call! Global Startups to Get on Board EPIC 2025 Supported by 20 global financial and corporate partners collectively managing an AUM close to US$100B and operating across Asia, Europe and North America, EPIC 2025 offers an unprecedented US$100M targeted funding pool, US$240,000 cash prizes, and an extensive experience for mid- to late-stage startups to grow from regional names to international labels: Key Dates Application Period: Now to 17 June 2025, 23:59 (GMT+8) Online Regional Pitch: July 2025 Finalist Announcement: August 2025 EPIC Week in Hong Kong: 3 – 7 November 2025 Mid- to late-stage startups under 10 years old, focused on Digital Health Tech, FinTech, or GreenTech, and registered as businesses with plans to expand R&D or operations to Hong Kong and/or the Greater Bay Area (GBA), are eligible to enter for EPIC. As the journey moves along, a series of highlights in the week-long EPIC Week will be made available to finalists speeding for the finish line, including Tech Spotlight for a showcase of their innovative solutions exclusive to potential investors and corporate decision-makers, in engaging instant and in-depth conversations; and the Greater Bay Area Exploration for a guided tour of a glimpse into the vast opportunities in the GBA and beyond—where complimentary flight and accommodation sponsored (*T&C applies) for contestants overseas. Albert Wong, CEO of HKSTP said: 'Following the success of EPIC 2024 receiving applause from 47 economies, making it a more impactful event is where we're going this year, as well as more inclusive, which is why we're having new tech tracks, at a new location in Hong Kong, with new formats, yet one thing remains the same—it is an opportunity you don't want to miss.' Global application for EPIC 2025 is opened until 17 June 2025, 23:59 (GMT+8). For details, please visit for more. Hashtag: #HKSTP #EPIC2025 The issuer is solely responsible for the content of this announcement. About Hong Kong Science and Technology Parks Corporation Hong Kong Science and Technology Parks Corporation (HKSTP) is a statutory body leading as one of the world's most dynamic innovation and technology ecosystems, powering through a future with the united force of over 24,000 visionaries working at more than 2,300 tech companies from 25 countries and regions, across multiple locations including Hong Kong Science Park, InnoCentre, Hong Kong Science Park Shenzhen Branch, and the InnoParks. From R&D infrastructure and investment opportunities, to industry networks and talent traction, HKSTP offers comprehensive support that translates innovative ideas to commercialisable solutions. With 13 unicorns and dozens of world-firsts, HKSTP will continue the momentum calling for global innovators to join the community with Keep Up spirits. More information about HSKTP is available at
Malay Mail
28-05-2025
- Business
- Malay Mail
Last Call! Global Startups to Get on Board EPIC 2025
Don't Miss Out on the Million-dollar Opportunity at Asia's Most Dynamic Ecosystem Last Call! Global Startups to Get on Board EPIC 2025 Key Dates Finalist Announcement: August 2025 EPIC Week in Hong Kong: 3 – 7 November 2025 HONG KONG SAR - Media OutReach Newswire - 28 May 2025 - The 9th Elevator Pitch International Competition (EPIC 2025), organised by Hong Kong Science and Technology Parks Corporation (HKSTP), has only 3 weeks left for global startups with their anchor in FinTech, and new tech tracks Digital Health and Green Tech, respond to the call to one of Asia's largest innovation arenas. Participants will 60-second pitch their way to business matching and investment opportunities for a lift towards by 20 global financial and corporate partners collectively managing an AUM close to US$100B and operating across Asia, Europe and North America, EPIC 2025 offers an unprecedented US$100M targeted funding pool, US$240,000 cash prizes, and an extensive experience for mid- to late-stage startups to grow from regional names to international labels:Now to 17 June 2025, 23:59 (GMT+8)July 2025As the journey moves along, a series of highlights in the week-long EPIC Week will be made available to finalists speeding for the finish line, including Tech Spotlight for a showcase of their innovative solutions exclusive to potential investors and corporate decision-makers, in engaging instant and in-depth conversations; and the Greater Bay Area Exploration for a guided tour of a glimpse into the vast opportunities in the GBA and beyond—where complimentary flight and accommodation sponsored (*) for contestants Wong, CEO of HKSTP said: "Following the success of EPIC 2024 receiving applause from 47 economies, making it a more impactful event is where we're going this year, as well as more inclusive, which is why we're having new tech tracks, at a new location in Hong Kong, with new formats, yet one thing remains the same—it is an opportunity you don't want to miss." Global application for EPIC 2025 is opened until 17 June 2025, 23:59 (GMT+8). For details, please visit for #HKSTP #EPIC2025 The issuer is solely responsible for the content of this announcement. About Hong Kong Science and Technology Parks Corporation Hong Kong Science and Technology Parks Corporation (HKSTP) is a statutory body leading as one of the world's most dynamic innovation and technology ecosystems, powering through a future with the united force of over 24,000 visionaries working at more than 2,300 tech companies from 25 countries and regions, across multiple locations including Hong Kong Science Park, InnoCentre, Hong Kong Science Park Shenzhen Branch, and the InnoParks. From R&D infrastructure and investment opportunities, to industry networks and talent traction, HKSTP offers comprehensive support that translates innovative ideas to commercialisable solutions. With 13 unicorns and dozens of world-firsts, HKSTP will continue the momentum calling for global innovators to join the community with Keep Up spirits. More information about HSKTP is available at
Zawya
28-05-2025
- Business
- Zawya
Last Call! Global Startups to Get on Board EPIC 2025
Don't Miss Out on the Million-dollar Opportunity at Asia's Most Dynamic Ecosystem HONG KONG SAR - Media OutReach Newswire - 28 May 2025 - The 9th Elevator Pitch International Competition (EPIC 2025), organised by Hong Kong Science and Technology Parks Corporation (HKSTP), has only 3 weeks left for global startups with their anchor in FinTech, and new tech tracks Digital Health and Green Tech, respond to the call to one of Asia's largest innovation arenas. Participants will 60-second pitch their way to business matching and investment opportunities for a lift towards success. Supported by 20 global financial and corporate partners collectively managing an AUM close to US$100B and operating across Asia, Europe and North America, EPIC 2025 offers an unprecedented US$100M targeted funding pool, US$240,000 cash prizes, and an extensive experience for mid- to late-stage startups to grow from regional names to international labels: Key Dates Application Period: Now to 17 June 2025, 23:59 (GMT+8) Online Regional Pitch: July 2025 Finalist Announcement: August 2025 EPIC Week in Hong Kong: 3 – 7 November 2025 Mid- to late-stage startups under 10 years old, focused on Digital Health Tech, FinTech, or GreenTech, and registered as businesses with plans to expand R&D or operations to Hong Kong and/or the Greater Bay Area (GBA), are eligible to enter for EPIC. As the journey moves along, a series of highlights in the week-long EPIC Week will be made available to finalists speeding for the finish line, including Tech Spotlight for a showcase of their innovative solutions exclusive to potential investors and corporate decision-makers, in engaging instant and in-depth conversations; and the Greater Bay Area Exploration for a guided tour of a glimpse into the vast opportunities in the GBA and beyond—where complimentary flight and accommodation sponsored (* T&C applies) for contestants overseas. Albert Wong, CEO of HKSTP said: "Following the success of EPIC 2024 receiving applause from 47 economies, making it a more impactful event is where we're going this year, as well as more inclusive, which is why we're having new tech tracks, at a new location in Hong Kong, with new formats, yet one thing remains the same—it is an opportunity you don't want to miss." Global application for EPIC 2025 is opened until 17 June 2025, 23:59 (GMT+8). For details, please visit for more. Hashtag: #HKSTP #EPIC2025 The issuer is solely responsible for the content of this announcement. About Hong Kong Science and Technology Parks Corporation Hong Kong Science and Technology Parks Corporation (HKSTP) is a statutory body leading as one of the world's most dynamic innovation and technology ecosystems, powering through a future with the united force of over 24,000 visionaries working at more than 2,300 tech companies from 25 countries and regions, across multiple locations including Hong Kong Science Park, InnoCentre, Hong Kong Science Park Shenzhen Branch, and the InnoParks. From R&D infrastructure and investment opportunities, to industry networks and talent traction, HKSTP offers comprehensive support that translates innovative ideas to commercialisable solutions. With 13 unicorns and dozens of world-firsts, HKSTP will continue the momentum calling for global innovators to join the community with Keep Up spirits. More information about HSKTP is available at Hong Kong Science and Technology Parks Corporation
Yahoo
19-05-2025
- Business
- Yahoo
DocGo Wins "Compliance Management Innovation Award" in 2025 MedTech Breakthrough Awards Program
Prestigious International Annual Awards Program Recognizes Standout Digital Health & Medical Technology Products and Companies NEW YORK, May 19, 2025--(BUSINESS WIRE)--DocGo Inc. (Nasdaq: DCGO) ("DocGo"), a leading provider of technology-enabled mobile health services, today announced that it has been selected as winner of the "Compliance Management Innovation Award" in the 9th annual MedTech Breakthrough Awards program conducted by MedTech Breakthrough, an independent market intelligence organization that recognizes the top companies, technologies and products in the global digital health and medical technology market. DocGo's breakthrough Compliance Program excels at adapting to the organization's dynamic environment and consistently updating its strategies to address emerging risks and technologies. The program's approach focuses on managing ethics, compliance, and risk management to strengthen corporate culture, drive results, and promote transparency and accountability within the healthcare industry. DocGo's Compliance Program ensures alignment with industry standards and federal and state regulations, even as the organization scales rapidly and introduces innovative solutions to the healthcare industry. The program's annual compliance survey, a key component, provides employees with an additional confidential channel to report concerns and share feedback. "Our Compliance Program has been an essential component in the success of our organization, and is built on the foundation of organizational excellence. Along with transparency and ethical practices, our approach remains focused on fostering a culture of trust," said Stephen Sugrue, DocGo's Chief Compliance Officer. "We're grateful to MedTech Breakthrough for this recognition, and we remain committed to delivering high quality, highly accessible healthcare to all, and through our meticulously crafted Compliance Program, to do so ethically." The MedTech Breakthrough Awards program celebrates excellence and innovation in the health and medical technology industry, recognizing the companies, products, and solutions driving meaningful progress and improving patient care. Spanning a wide range of categories—including Telehealth, Clinical Administration, Patient Engagement, Electronic Health Records (EHR), Virtual Care, Medical Devices, Medical Data & Privacy, and beyond—the awards highlight the groundbreaking work that is transforming the healthcare landscape. This year's program saw a record-breaking number of nominations from leading companies and startups across more than 18 countries, showcasing the global impact and momentum of the digital healthcare industry today. "DocGo's approach to compliance offers innovative strategies to consistently build a strong foundation. Healthcare organizations need to implement and streamline policies and procedures that address emerging issues and ensure compliance with regulatory standards. From patient safety to care quality, to employee satisfaction, the right policies build trust and reputation," said Steve Johansson, managing director, MedTech Breakthrough. "DocGo's Compliance Program has all the hallmarks of a well-designed program with ample resources, empowerment, and the evidence of working incredibly well in practice. We're thrilled to award them our 2025 'Compliance Management Innovation Award!'" By incorporating the Department of Justice (DOJ) 2024 Evaluation of Corporate Compliance Programs, DocGo's program has been able to further improve its effectiveness strategies. This guidance has been the model framework in building the 2025 Compliance & Audit Work Plan, a valuable resource that assesses the program based on the DOJ's risk strategy initiatives. The work plan has been enhanced with various risk assessments conducted by key stakeholders, as well as incorporating and handling risks with new and emerging technology, and streamlining cybersecurity procedures to improve HIPAA privacy objectives. About DocGoDocGo is leading the proactive healthcare revolution with an innovative care delivery platform that includes mobile health services, remote patient monitoring and medical transport solutions. DocGo is helping to reshape the traditional four-wall healthcare system by providing high quality, highly accessible care to patients where and when they need it. DocGo's proprietary technology and relationships with a dedicated field staff of certified health professionals elevate the quality of patient care and drive business efficiencies for facilities, hospital networks and health insurance providers. With Mobile Health, DocGo empowers the full promise and potential of telehealth by facilitating healthcare treatment, in tandem with a remote physician, in the comfort of a patient's home or workplace. Together with DocGo's integrated Ambulnz medical transport services, DocGo is bridging the gap between physical and virtual care. For more information, please visit To get an inside look on how the proactive healthcare revolution is helping transform healthcare by reducing costs, increasing efficiency and improving outcomes, visit About MedTech BreakthroughPart of Tech Breakthrough, a leading market intelligence and recognition platform for global technology innovation and leadership, the MedTech Breakthrough Awards program is devoted to honoring excellence and innovation in medical & health technology companies, products, services and people. The MedTech Breakthrough Awards provide a platform for public recognition around the achievements of breakthrough healthcare and medical companies and products in categories that include Patient Experience & Engagement, Health & Fitness, Medical Devices, Clinical Administration, Connected Healthcare, Medical Data, Healthcare Cybersecurity and more. For more information visit Tech Breakthrough LLC does not endorse any vendor, product or service depicted in our recognition programs, and does not advise technology users to select only those vendors with award designations. Tech Breakthrough LLC recognition consists of the opinions of the Tech Breakthrough LLC organization and should not be construed as statements of fact. Tech Breakthrough LLC disclaims all warranties, expressed or implied, with respect to this recognition program, including any warranties of merchantability or fitness for a particular purpose. View source version on Contacts Investors: Mike ir@ Sign in to access your portfolio
